Eventide Asset Management, a Boston-based investment adviser, led a $120m funding round in Biosplice Therapeutics, a private biopharmaceutical company, with participation from aMoon, SymBiosis II, Sands Capital and Verition Fund Management. “We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice. This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. In addition, we expect to realize the tremendous potential of our oncology program, as well as neurology and other areas of significant unmet need,” Cevdet Samikoglu, Biosplice CEO.